Coding and noncoding somatic mutations in basal cell carcinoma
Maria Giovanna Maturo(University of L'Aquila), Rajiv Ranjan Kumar(DR. B.R.A. Institute Rotary Cancer Hospital), Cristina Pellegrini(University of L'Aquila), B. Llombart(Fundación Instituto Valenciano de Oncología), Sivaramakrishna Rachakonda(German Cancer Research Center), Lucia Di Nardo(Università Cattolica del Sacro Cuore), Maria Concetta Fargnoli(University of L'Aquila), Eduardo Nagore(Valencia Catholic University Saint Vincent Martyr), Celia Requena(Fundación Instituto Valenciano de Oncología), C. Serra‐Guillén(Fundación Instituto Valenciano de Oncología), Ketty Peris(Agostino Gemelli University Polyclinic), Nalini Srinivas(German Cancer Research Center), Carlos Guillén(Fundación Instituto Valenciano de Oncología), Onofre Sanmartín(Fundación Instituto Valenciano de Oncología), Barbara Heidenreich(German Cancer Research Center)
Cited by 0
Related Papers
Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2)*
|British Journal of Dermatology|2020|590
Diagnosis and treatment of basal cell carcinoma: European consensus–based interdisciplinary guidelines
|European Journal of Cancer|2019|589
Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline – Update 2016
|European Journal of Cancer|2016|579
European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 2. Treatment
|European Journal of Cancer|2020|324
European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics: Update 2022
|European Journal of Cancer|2022|320